More on Vermillion (VRML): Q3 beats bottom line consensus on lower-than-anticipated losses. Revenue was flat on a Y/Y basis, while earnings got a big boost from better cost controls. Operating expenses decreased by nearly half as compared to the prior year period, driven by lower clinical trial costs, fewer legal expenses and ongoing cost containment initiatives. Shares +7.5% AH.
More on Vermillion (VRML): Q3 beats bottom line consensus on lower-than-anticipated losses....
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs